BS_KR4MP5ET
Meningioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Meningioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Meningioma
- overall_survival_months
- 75.16425755584757
- age_years
- 0.573
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.567
- INTERFERON_ALPHA_RESPONSE+0.404
- INTERFERON_GAMMA_RESPONSE+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.395
- GLYCOLYSIS+0.390
- ANGIOGENESIS+0.375
- MTORC1_SIGNALING+0.367
- OXIDATIVE_PHOSPHORYLATION+0.350
- COAGULATION+0.347
- APICAL_JUNCTION+0.343
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.249
- KRAS_SIGNALING_DN-0.230
- SPERMATOGENESIS-0.166
- BILE_ACID_METABOLISM-0.076
- PANCREAS_BETA_CELLS-0.071
- HEME_METABOLISM-0.001
- PEROXISOME+0.036
- KRAS_SIGNALING_UP+0.076
- MYOGENESIS+0.085
- FATTY_ACID_METABOLISM+0.116
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | F9EB85A8-8E6D-44C0-8C59-50B1DB4E652B | — | — | 0.944 |
| 2 | E9FC1686-028B-476C-B51B-4956213D874B | — | — | 0.943 |
| 3 | AA762299-102B-4E35-B4A5-A94A122EF9DB | — | — | 0.943 |
| 4 | DE370889-1057-4355-AFD8-CCFCDC6CD00F | — | — | 0.935 |
| 5 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.935 |
| 6 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.933 |
| 7 | 3D3C3AAA-2C7A-43C6-8137-73A6E0896FAC | — | — | 0.932 |
| 8 | 228C2042-804C-47FA-B565-1993E1015D40 | — | — | 0.931 |
| 9 | C6A60028-2402-4048-90DF-F2B3712FB530 | — | — | 0.931 |
| 10 | SRR934958 | — | — | 0.929 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.567 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.404 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.395 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.390 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.375 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.367 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| COAGULATION | 0.347 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.343 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.342 | Inavolisib | — uncovered |
| HYPOXIA | 0.336 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.334 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.332 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.332 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.331 | Inavolisib | — uncovered |
| APOPTOSIS | 0.311 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.304 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.302 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.295 | Idelalisib | — uncovered |